The influence of bivalirudin in coronary blood flow during primary percutaneous coronary intervention for acute myocardial infarction
10.3969/j.issn.1004-8812.2017.11.001
- VernacularTitle:比伐芦定对急性心肌梗死直接经皮冠状动脉介入治疗中冠状动脉血流的影响
- Author:
huai Chong GU
1
,
2
;
安徽安庆,安庆市立医院心血管内科
;
Xin ZHAO
;
yang Yu DENG
;
min Quan JING
;
zeng Xiao WANG
;
yan Ying MA
;
wei Hai LIU
;
Kai XU
;
Bin WANG
;
ling Ya HAN
Author Information
1. 110016 辽宁沈阳,沈阳军区总医院心内科
2. 安徽安庆,安庆市立医院心血管内科
- Keywords:
Bivalirudin;
Heparin;
Acute myocardial infarction;
Percutaneous coronary intervention
- From:
Chinese Journal of Interventional Cardiology
2017;25(11):601-609
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy of bivalirudin on reperfusion of coronary artery in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Methods In our study, we evaluated 245 patients with acute myocardial infarction who underwent percutaneous coronary intervention between April 2012 to May 2015. Based on the therapy during operation, bivalirudin were used in 122 patients and heparin was used in 123 patients. Study outcomes included immediate TIMI(thrombolysis in myocardial infarction)flow and CTFC(Corrected TIMI Frame Count)by angiogrophy once the target lesion was opened rates of ,in-hospital thrombocytopenia, bleeding events myocardial infarction, repeat revascularization and the incidence of MACE(major adverse cardiac events)in 30 days and 1 year. Results The mean heart rate was higher in the bivalirudin group(P=0.034). There was no significant difference between the two groups in laboratory results or interventional data(P>0.05). After the target vessel was opened, the effect of bivalirudin on slow/no-reflow in primary PCI has no difference between heparin in terms of TIMI blood evaluation or CTFC (P>0.05). Hospitalization data analysis showed that bivalirudin was able to obtain a higher activated whole blood coagulation time(ACT)value(P<0.001)with lower decrease in the number of platelets. Follow-up data of 30 days and 1 year showed no difference in the incidence of MACE and net adverse clinical events(NACE)between the two groups(P>0.05). Conclusions Bivalirudin has well efficacy and safety in patients with acute myocardial infarction in patients with acute myocardial infarction undergoing PPCI without increasing the incidence of slow/no-reflow.
